GoodRx Holdings, Inc. — Director's Dealing 2021

Sep 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GoodRx Holdings, Inc. (GDRX)
CIK: 0001809519
Period of Report: 2021-09-14

Reporting Person: NAGJI BANSI (President, Healthcare)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-14	Class A Common Stock	M	89797	$6.84	Acquired	89797	Direct
2021-09-14	Class A Common Stock	S	89797	$45.0129	Disposed	0	Direct
2021-09-15	Class A Common Stock	M	60415	$6.84	Acquired	60415	Direct
2021-09-15	Class A Common Stock	S	60415	$45.0288	Disposed	0	Direct
2021-09-16	Class A Common Stock	M	29788	$6.84	Acquired	29788	Direct
2021-09-16	Class A Common Stock	S	29788	$45.0345	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-14	Stock Option (Right to Buy)	$6.84	M	89584	Disposed	2030-06-15	Class A Common Stock (89797)	Direct
2021-09-14	Stock Option (Right to Buy)	$6.84	M	213	Disposed	2030-06-15	Class A Common Stock (213)	Direct
2021-09-15	Stock Option (Right to Buy)	$6.84	M	60415	Disposed	2030-06-15	Class A Common Stock (60415)	Direct
2021-09-16	Stock Option (Right to Buy)	$6.84	M	29788	Disposed	2030-06-15	Class A Common Stock (29788)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.11. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.24. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.13. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The option has vested and became exercisable or will vest and become exercisable with respect to the original 700,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on June 10, 2020.

F6: The option vested and became exercisable as to 25,000 shares on the closing date of the Issuer's initial public offering of securities, and vested or will vest as to 1/48th of the shares monthly thereafter until fully vested on June 10, 2024.